<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03031717</url>
  </required_header>
  <id_info>
    <org_study_id>TIPS-NEOPORTA</org_study_id>
    <nct_id>NCT03031717</nct_id>
  </id_info>
  <brief_title>Clinical Course of Cirrhotic Patients With Portal Vein Thrombosis Treated With TIPS</brief_title>
  <official_title>Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <brief_summary>
    <textblock>
      Portal vein thrombosis (PVT) is defined as an obstruction of the portal vein. The prevalence
      of PVT is 10-25% and incidence is about 16% in cirrhotic patients. PVT leads to increased
      intrahepatic resistance, decreased portal velocities, splanchnic vasodilatation, and stagnant
      flow.

      Portal vein recanalization (PVR) with transjugular intrahepatic portosystemic shunt (TIPS) is
      aimed at restoring main portal vein (PV) flow in chronic PVT. In this study, we will review
      the safety and outcomes of this approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal vein thrombosis (PVT) is a fairly common complication of liver cirrhosis. Importantly,
      occlusive PVT might influence the prognosis of patients with cirrhosis. Transjugular
      intrahepatic portosystemic shunt (TIPS) has been reported to be an effective treatment of PVT
      in cirrhosis, with the advantage of avoiding the risk of bleeding linked to anticoagulation.
      In this study, we will evaluate the outcome of TIPS for PVT in patients with and without
      cirrhosis and determinate survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome of TIPS for PVT in patients with and without cirrhosis</measure>
    <time_frame>5 years</time_frame>
    <description>Clinical evolution after placement of TIPS</description>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Portal Vein Thrombosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transjugular intrahepatic portosystemic shunt</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      3 capillary blood tubes of 4.0 ml Inflammation cytokines will be analyzed (IL-1, IL-6, FNTa)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with portal vein thrombosis and with or without liver cirrhosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Liver cirrosis or non-cirrhotic patients

          -  Portal vein thrombosis (degree of vessel obstruction &gt; 50%)

        Exclusion Criteria:

          -  Active variceal bleeding

          -  Prior history of TIPS placement or shunt surgery

          -  Concomitant renal insufficiency

          -  Severe cardiopulmonary diseases

          -  Uncontrolled sepsis Serious medical conditions which may reduce the life expectancy

          -  Contraindications for TIPS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre Delgadillo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aldo Torre Delgadillo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldo Torre</last_name>
    <phone>54870900</phone>
    <email>detoal@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aldo Torre Delgadillo</last_name>
    <email>detoal@yahoo.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Torre Delgadillo, M.D. M.Sc</last_name>
      <phone>54870900</phone>
      <phone_ext>2711</phone_ext>
      <email>detoal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aldo Torre-Delgadillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

